Autolus Therapeutics' AUCATZYL Approvals and Revenue Guidance Redefine Long-Term Story

Autolus Therapeutics reported preliminary 2025 net product revenue of $75,000,000 and 2026 guidance of $120,000,000-$135,000,000, alongside securing UK and EU approvals for AUCATZYL. The company is coupling early commercial traction with manufacturing upgrades and broader obe-cel trial expansion to support its long-term product and pipeline ambitions. Investors should be aware of the near-term risk around high manufacturing costs and the path to sustainable margins and funding.